Radioimmunoassays for prostaglandins. II. Measurement of prostaglandin E2 and the 13,14-dihydro-15-keto metabolites of the E and F series. Description of a reliable technique with a universal applicability

Thomas, Chris M.G.; Berg, R. J. Van Den; Gans, H.J. de Koning; Lequin, R. M.

doi:10.1016/0090-6980(78)90151-x

Cited by 18 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following variables were measured in each blood sample: serum thromboxane B 2 , whole blood platelet aggregation, closure time, serum creatinine, platelet count, and hematocrit. Thromboxane B 2 concentrations in serum were determined in duplicate by radioimmunoassay 26 , 27 . As a measure of assay precision, intraassay and interassay coefficients of variations were 8.1% and 12.5%, respectively 28 .…”

Section: Methodsmentioning

confidence: 99%

Meloxicam, 15 mg/day, spares platelet function in healthy volunteers*1

DEMEIJER

1999

Clinical Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Meloxicam, 15 mg/day, spares platelet function in healthy volunteers*1

DEMEIJER

1999

Clinical Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…The levels of PGE 2, PGF2~, 6-keto-PGFa, and TxB2 were determined by radioimmunoassays, according to procedures described previously [20,21]. After 10 consecutive assays the PGE2 determinations showed 6.4 and 15%, the PGF2, assay 5.3 and 11%, the 6-keto-PGFl~ assay 7.3 and 9.6%, and the TxB 2 assay 8.1 and 12.5% intra-and interassay variability, respectively.…”

Section: Methodsmentioning

confidence: 99%

Urinary prostaglandin and prostaglandin metabolite excretion in patients with essential hypertension or hypertension with renal artery stenosis

Postma

Boo²,

Thomas

et al. 1995

The Netherlands Journal of Medicine

View full text Add to dashboard Cite

Background: Recent studies have reported elevated prostaglandin levels in patients with renal artery stenosis and hypertension. To investigate whether a distinction between essential hypertension and hypertension with renal artery stenosis is possible by measuring eicosanoid excretion, we studied the excretion of these compounds in patients with essential hypertension and in hypertensives with concomitant renal artery stenosis.Methods: The 24-h urinary excretion of metabolites of prostaglandin I2, prostaglandin E 2 and metabolites of thromboxane A 2 was sampled under standardised conditions, in 15 patients with essential hypertension and in 15 patients with unilateral renal artery stenosis with hypertension. Also clinical and biochemical characteristics of the subjects were analysed.Results: The patients with renal artery stenosis had significantly lower excretion of prostaglandin I 2 than did the essential hypertensive patients. However, the overlap in the values was large, thus not allowing a diagnostic differentiation according to urinary prostaglandin I z levels. The excretion of prostaglandin E 2 and of metabolites of thromboxane A 2 showed no significant differences among the groups.Conclusions: Measurement of urinary prostaglandin or prostaglandin metabolite excretion did not contribute to the non-invasive detection of the presence of a renal artery stenosis in the patients in this study.

show abstract

“…The mean arterial blood pressure (MAP) was calculated as the sum of the diastolic blood pressure and one‐third of the pulse pressure. The PRA and 6KPGF 1 α were measured by radioimmunoassay [14–16], and ACE by colorimetry [17]. Statistical analysis was performed with the Student's paired sample t ‐test a, while for PRA and excretion of 6KPGF 1 α the Wilcoxon test for paired data was used; P < 0.05 was considered as statistically significant.…”

Section: Study Population and Methodsmentioning

confidence: 99%

The interaction between indomethacin and captopril or enalapril in healthy volunteers

Koopmans

Megen

Thien

et al. 1989

Journal of Internal Medicine

View full text Add to dashboard Cite

In this study eight healthy volunteers were involved in a randomized, cross-over trial in which they were treated with either 25 mg of captopril b.i.d. or 20 mg of enalapril o.i.d. alone or in combination with 50 mg of indomethacin b.i.d. in order to detect a difference between both converting enzyme inhibitors when interacting with indomethacin. Before and after each 4-d treatment period, blood pressure (determined by random zero sphygmomanometer), body weight, plasma renin activity, angiotensin converting enzyme, plasma potassium, serum creatinine and the 24-h urinary excretion of 6-keto-prostaglandin F1 alpha were measured. Indomethacin attenuated the decrease of supine diastolic blood pressure during treatment with captopril, but not with enalapril. However, the initial decrease of blood pressure on captopril was greater than on enalapril. Both converting enzyme inhibitors had no effect on the urinary excretion of 6-keto-prostaglandin F1 alpha, while indomethacin reduced it. The results suggest a difference between captopril and enalapril in interaction with indomethacin.

show abstract

Radioimmunoassays for prostaglandins. II. Measurement of prostaglandin E2 and the 13,14-dihydro-15-keto metabolites of the E and F series. Description of a reliable technique with a universal applicability

Cited by 18 publications

References 1 publication

Meloxicam, 15 mg/day, spares platelet function in healthy volunteers*1

Meloxicam, 15 mg/day, spares platelet function in healthy volunteers*1

Urinary prostaglandin and prostaglandin metabolite excretion in patients with essential hypertension or hypertension with renal artery stenosis

The interaction between indomethacin and captopril or enalapril in healthy volunteers

Contact Info

Product

Resources

About